1. Optimisation of in silico derived 2-aminobenzimidazole hits as unprecedented selective kappa opioid receptor agonists.
- Author
-
Sasmal, Pradip K., Krishna, C. Vamsee, Adabala, S. Sudheerkumar, Roshaiah, M., Rawoof, Khaji Abdul, Thadi, Emima, Sukumar, K. Pavan, Cheera, Srisailam, Abbineni, Chandrasekhar, Rao, K.V.L. Narasimha, Prasanthi, A., Nijhawan, Kamal, Jaleel, Mahaboobi, Iyer, Lakshmi Ramachandran, Chaitanya, T. Krishna, Tiwari, Nirbhay Kumar, Krishna, N. Lavanya, Potluri, Vijay, Khanna, Ish, and Frimurer, Thomas M.
- Subjects
- *
PROCESS optimization , *BENZIMIDAZOLES , *OPIOID receptors , *CHEMICAL synthesis , *CHEMICAL derivatives - Abstract
Kappa opioid receptor (KOR) is an important mediator of pain signaling and it is targeted for the treatment of various pains. Pharmacophore based mining of databases led to the identification of 2-aminobenzimidazole derivative as KOR agonists with selectivity over the other opioid receptors DOR and MOR. A short SAR exploration with the objective of identifying more polar and hence less brain penetrant agonists is described herewith. Modeling studies of the recently published structures of KOR, DOR and MOR are used to explain the receptor selectivity. The synthesis, biological evaluation and SAR of novel benzimidazole derivatives as KOR agonists are described. The in vivo proof of principle for anti-nociceptive effect with a lead compound from this series is exemplified. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF